Noun
pembrolizumab (uncountable)
(pharmacology) A drug that targets the programmed cell death 1 (PD-1) receptor, intended for use in treating metastatic melanoma.
The clinical benefit of pembrolizumab in advanced thyroid cancer will be further studied in a follow-up phase II clinical trial that is now ongoing to try to discover biomarkers which predict response to treatment with pembrolizumab. Source: Internet
The biomarker cut point will need to be validated in the larger study population, but seems to identify patients most likely to respond to pembrolizumab well. Source: Internet
The phase II KEYNOTE-052 trial evaluated the efficacy and safety of PD-1 blockade with pembrolizumab as first line therapy in cisplatin ineligible patients with metastatic or locally advanced bladder cancer. Source: Internet